RDS has secured €14 million ($16.6 million) in a Series A funding round led by the SPI (Sociétés de Projets Industriels) fund, managed on behalf of the French state by Bpifrance. Critical Path Ventures lended its support for the first time, and returning investors MACSF and Capital Grand Est also contributed.
 
RDS’ lead product is MultiSense, a CE-marked, class IIa remote monitoring medical device that provides healthcare professionals with a high-precision, comprehensive solution for continuously monitoring patients’ key physiological parameters in the hospital or at home. This clinically validated technology has already been rolled out in 15 hospitals across France, Belgium, and Germany. In the last year, the device was added to the approved supplies list for RESAH and UniHA—public purchasing bodies for hospitals in France. 

“We are delighted to be supporting RDS in this critical phase of its development,” said Magali Joëssel, director of the SPI fund at Bpifrance. “This funding gives the company the means to become a leading player in post-operative remote monitoring through MultiSense, and a pioneer in the medicine of the future. By scaling the manufacturing of its solution, RDS fully embodies the principle of the SPI fund: funding the industrialization of innovative technologies that will bring growth and jobs to France.”

RDS will use the funds to accelerate MultiSense’s development in France, Germany, and the broader European market. The company expects to create several hundred new jobs by 2035, bolstering its sales team to meet growing demand for the MultiSense solution. The funds will also finance the solution’s industrialization (now manufactured in France), with the goal of gradually ramping up production and refurbishing capacities. 
 
Simultaneously, RDS will launch complementary clinical trials to support its applications for reimbursement in France and across Europe. The company is also preparing to initiate the U.S. Food and Drug Administration registration process in preparation for a U.S. market launch in 2028.
 
“This investment gives us the means to ramp up our sales growth in Europe, consolidate the clinical and health economic value of MultiSense, and get ready for market launch in North America,” RDS CEO Elie Lobel stated. “These funds mean we can roll out our solution more widely to hospitals, expand its positive impact for patients and care teams, and provide reliable, continuous, clinically validated remote monitoring to as many facilities as possible. The funds raised are a testament to our investors’ confidence in this project and the team.”
 
With this financing, RDS will have raised €28 million in total since its founding. The Series A €14 million is separate from the €14 million in capital and non-dilutive financing provided by the French government, notably through the France 2030 investment plan, as well as by the Grand-Est regional authority and the European Union, within the scope of several research projects.
 
“France 2030 is proud to have supported this project since 2020 and to work today with SPI on the rapid industrialization and effective deployment of the solution for the benefit of patients. RDS’ story clearly shows how France 2030 is capable of transitioning a project from the lab stage to becoming an international champion,” said Bruno Bonnell, secretary general for Investment, in charge of France 2030.
 
In parallel with the funding round, Laurent Monnin, senior investment director at Bpifrance, and Nicolas Foessel of Critical Path Ventures join RDS’s Board of Directors.
 
“We believe the key to transforming the healthcare system is useful innovation and industrial ambition,” Foessel said. “With our investment in RDS, we are backing a team that combines technological excellence with clinical impact and a long-term vision for medicine, with emphasis on a more preventive, smoother and human approach. MultiSense exemplifies this positioning, enabling continuous monitoring and meeting patients’ particular needs away from the hospital setting.”
 
“The funding provided by SPI and Critical Path Ventures is a real asset for RDS, which will be able to ramp-up activities after a launch phase to which MACSF and Capital Grand Est have contributed,” Capital Grand Est. Partner Jean-François Rax added.
 
The global market for vital signs monitoring is estimated at $15 billion in 2025, and expected to grow by an average 15% annually through 2030. This progression reflects a strong shift towards home-based patient care both in France and internationally, driven by the desire to relieve pressure on hospitals, reduce duration of stay, and improve post-operative monitoring. The COVID-19 pandemic also brought about a significant shift in outlook, accelerating the adoption of remote monitoring and strengthening the requirement for reliable, interoperable digital solutions.
 
“ERAS (Enhanced Recovery After Surgery) studies have shown the importance of short hospital stays, even after a major surgery. However, the use of these protocols remains limited because surgeons have to engage their responsibility. The MultiSense patch offers an ideal solution: faster patient discharge and a more effective monitoring of vital signs than in hospital, with considerable medical and economic benefits expected. This is a major challenge for the sustainability of our healthcare system,” concluded Jacques Marescaux, professor of surgery, president/founder of IRCAD, and RDS Scientific Board member.
 
The MultiSense solution combines a wearable patch with a cloud-based platform and associated support services. It continuously monitors six key parameters, including heart rate, respiratory rate, and oxygen saturation. The solution is protected by more than 20 patents. From the outset, sustainability has been a core focus: the device can be cleaned, refurbished and reused to minimize its carbon footprint. MultiSense is designed to support the implementation of short-stay hospitalization protocols, helping to reduce the average length of hospital stays, to ensure safer hospital discharge and to improve patients’ quality of life. MultiSense carries a CE mark but does not benefit from reimbursement at this time.
 
Bpifrance finances companies—at each stage of their development—in credit, guarantees, and equity. It supports them in their innovation and international projects. Bpifrance also ensures their export activity through various products. Consulting, university, networking and acceleration programs for startups, SMEs, and midcaps are also part of the offer available to entrepreneurs. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, unique and efficient contact person to help them face their challenges.

The SPI fund, managed by Bpifrance on behalf of the French state in connection with the France 2030 plan, helps industrial projects with the best business and employment opportunities for industrial sectors find support for their development. The fund acts as an informed investor taking stakes in project companies with industrialization projects, which are selected for their growth potential, the current positioning of the industry, and their contribution to the environmental and energy transition. As such, it is one of the financial levers of the New Industrial France (Nouvelle France Industrielle) policy.
 
Since 2022, Critical Path Ventures has been investing in innovative scientific research projects, providing financial support to startups created by researcher-entrepreneurs from the seed stage onwards.
Critical Path Ventures selects an average of six projects per year, often on a co-investment basis and mainly in the fields of physics, medicine, biotechnology, and robotics, promoting industrial development and job retention in France.
 
France’s leading insurer for health care professionals, MACSF (Mutuelle d’assurance du corps de santé français) has more than a century of experience providing services to all those employed in healthcare occupations. It employs 1,700 people and generates more than €3 billion ($3.5 billion) in revenue. In keeping with its mission as a professional mutual insurer, MACSF provides cover for personal and occupational risks for over one million members and customers.
 
Capital Grand Est is an independent regional investment capital company accredited by the French Financial Markets Authority (AMF). Since 2012, its 14-strong team has provided support to more than 70 companies in France’s Grand Est and Bourgogne-Franche-Comté regions. With more than €220 million ($259.5 million) in assets under management across six investment vehicles, Capital Grand Est organizes various capital transactions for different business types in the region to accelerate their paths to success. It offers capital-intensive seed round support for innovative young startups. For more established companies, it structures development capital transactions to expedite their growth and buyouts to support them in their capital developments. Finally, for companies in transition, it organizes a capital rebound operation to consolidate the steps taken and promote the rebound of their business.
 
RDS specializes in remote patient monitoring—developing, manufacturing, and marketing MultiSense, a next-generation remote medical monitoring solution. Headquartered in Strasbourg (France) within the IHU, RDS relies on an international team and collaborates with major research projects such as DARE and 5G-OR. Winner of several awards, including the 2020 i-Lab prize, the Grand Prix de l’Académie des Technologies 2022 and the 2023 i-Nov prize, RDS stands out for its commitment to innovation and the digital transformation of healthcare. Incubated at SEMIA/Quest for Health and accelerated by PariSanté Campus, it aims to redefine telemonitoring standards through patented technology and an eco-conscious approach. 
 
The France 2030 investment plan has a dual ambition: to sustainably transform key sectors of the French economy (health, energy, automotive, aeronautics and space industries) through technological innovation, and to position France not just as a participant, but as a leader in shaping the world of tomorrow. From fundamental research to the emergence of an idea and the production of a new product or service, France 2030 supports the entire innovation lifecycle up to its industrialization. It is unprecedented in scale: €54 billion will be invested to ensure that French businesses, universities and research organizations successfully navigate transitions in these strategic industries. The goal: to enable them to respond competitively to the ecological and attractiveness challenges of the future and to foster the emergence of future leaders in French fields of excellence. France 2030 is defined by two overarching objectives: dedicating 50% of its expenditures to decarbonizing the economy and 50% to emerging actors driving innovation, without any spending detrimental to the environment.

France 2030 is overseen by the General Secretariat for Investment on behalf of the prime minister and implemented by the French Agency for Ecological Transition (ADEME), the National Research Agency (ANR), Bpifrance and the Banque des Territoires.